Preclinical Study of a Novel Tri-Specific Anti-CD3/CD19/CD20 T Cell-Engaging Antibody As a Potentially Better Treatment for NHL

CD20 癌症研究 CD19 医学 免疫学 抗体 B细胞
作者
Jie Zhang,Zhenhao Zhou
出处
期刊:Blood [American Society of Hematology]
卷期号:136 (Supplement 1): 22-22 被引量:8
标识
DOI:10.1182/blood-2020-140154
摘要

CD20 targeted therapy by means of anti-CD20 mAb is currently the most important regimen for treating B cells malignancies. However, 1-2% of B-cell lymphoma patients test negative for CD20. Besides, it has been reported in several studies that CD20 expression was down-regulated in over 20% of CD20-positive DLBCL patients that had relapsed/progressed after R-CHOP regimen. The limited prognosis for these patients poses a substantial unmet medical need. A new class of "1:2" format CD3 x CD20 bispecific antibodies emerged aiming for increased tumor antigen avidity and enhanced tumor cell killing, however, its advantages over conventional "1:1" format CD3 x CD20 antibodies have yet to be revealed in clinical trials. CMG1A46 is a 151 KD IgG-like "1:(1+1)" tri-specific antibody constructed on Chimagen's TRIAD platform. It simultaneously targets CD3 on T cell and two different biomarkers - CD20 and CD19 (abundancy of which proven to be intact post CD20-targeted treatment) - on tumor cells, recruiting T cells to kill tumor cells expressing CD19 and/or CD20. CMG1A46 is designed to target not only conventional CD19+CD20+ DLBCL, but also CD20-CD19+ DLBCL and DLBCL with trace to low expression of CD20 owing to its high avidity for tumor cells from 2 binders for CD19 and CD20 respectively. In vitro, CMG1A46 was shown to mediate tumor cell lysis by human PBMCs in a dose-dependent manner with EC50 around 0.3 pM. CMG1A46 was shown to have superior potency and safety (based on target-independent T cell activation) when compared to CD3 x CD20 bispecific antibodies with the conventional "1:1" IgG-based format. The antibody was able to induce potent tumor lysis in cells expressing both CD19 and CD20, and in cells expressing CD19 or CD20 alone. In vivo, 1A46 displayed potent tumor-suppressing activity in human PBMC-engrafted NOD mouse models and induced fast regression of large (CD19+CD20+) Jeko-1 lymphoma and (CD19+CD20-) A20-hCD19 tumors of ~100mm3. Remarkably, CMG1A46 can be administrated at the dosage 6 times as high as conventional CD3 x CD20 bispecific antibodies (3mg/kg for CMG1A46, 0.5mg/kg for conventional) and conferred even higher anti-tumor potency without any noticeable increase in toxicity (as evidenced by body weight of the animals and cytokine levels/T cell counts in serum post last administration). Pharmacokinetic studies in cyno monkeys show that when administrated at 1mpk CMG1A46 has a half-life that is over 70 hours in serum. After initial induction doses, weekly administration is able to maintain high circulating levels of the molecule. Dosages up to 10mpk do not lead to significant adverse effects. CMG1A46 treatment resulted in fast and complete elimination of B cells in peripheral blood within 24 hours after the first administration. Peripheral B cell elimination sustained for at least 28 days after last administration at 1mpk. B cell depletion was paralleled by transient decrease of T-cell counts in the peripheral blood and by the peak of cytokine release 4-8 hours after the first administration, followed by rapid recovery and return to baseline levels at 24 hours post treatment. Accordingly, CD3 receptor occupancy (RO) transiently increased during the induction phase and fell back to and sustained at a low level of around 20-30%. These studies show that CMG1A46 is a novel CD19/CD20-targeting T cell-engaging tri-specific antibody with very promising anti-tumor activity. In both in vitro and in vivo experiments, CMG1A46 demonstrated superior potency and safety compared to other CD3 x CD20 bispecific antibodies with the conventional "1:1" IgG format. Preliminary study in cyno monkeys suggested IgG-like half-life in serum and manageable toxicity. Taken together, the preclinical data strongly support for clinical testing of CMG1A46 in patients with CD20+ cancers. Phase 1 trial of the molecule is scheduled to start by April 2021. Disclosures No relevant conflicts of interest to declare.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yeyeming发布了新的文献求助10
刚刚
echasl73完成签到,获得积分10
刚刚
Lucas应助科研通管家采纳,获得10
1秒前
Jasper应助科研通管家采纳,获得10
1秒前
SciGPT应助科研通管家采纳,获得10
1秒前
SciGPT应助科研通管家采纳,获得10
1秒前
1秒前
NexusExplorer应助科研通管家采纳,获得30
1秒前
科研通AI2S应助科研通管家采纳,获得10
1秒前
Hello应助科研通管家采纳,获得10
1秒前
科研通AI2S应助科研通管家采纳,获得10
1秒前
itsserene应助科研通管家采纳,获得10
1秒前
1秒前
lucky发布了新的文献求助10
1秒前
斯文败类应助楚寅采纳,获得10
2秒前
笨笨的完成签到,获得积分10
2秒前
bkagyin应助小于采纳,获得10
2秒前
糊涂的雁易应助LV采纳,获得10
2秒前
小其发布了新的文献求助10
3秒前
5秒前
5秒前
xiaozhuan321完成签到,获得积分10
5秒前
好困应助Shuai采纳,获得10
5秒前
好困应助Shuai采纳,获得10
5秒前
好困应助Shuai采纳,获得10
5秒前
平常的凡白完成签到 ,获得积分10
5秒前
好困应助Shuai采纳,获得10
5秒前
6秒前
7秒前
白智妍完成签到,获得积分10
7秒前
7秒前
木子弓长发布了新的文献求助20
7秒前
yeyeming完成签到,获得积分10
7秒前
酷酷映冬完成签到 ,获得积分10
8秒前
精明的高跟鞋完成签到 ,获得积分10
8秒前
怡然念之完成签到 ,获得积分10
8秒前
9秒前
9秒前
10秒前
dangziutiu完成签到 ,获得积分10
11秒前
高分求助中
Evolution 10000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Foreign Policy of the French Second Empire: A Bibliography 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
China's Relations With Japan 1945-83: The Role of Liao Chengzhi 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3147695
求助须知:如何正确求助?哪些是违规求助? 2798784
关于积分的说明 7831337
捐赠科研通 2455622
什么是DOI,文献DOI怎么找? 1306889
科研通“疑难数据库(出版商)”最低求助积分说明 627943
版权声明 601587